. Author manuscript; available in PMC: 2012 Jan 2.

Published in final edited form as: Curr Hepat Rep. 2011 Jul 2;10(3):214–227. doi: 10.1007/s11901-011-0101-7

Table 2.

Viral dynamic parameter estimates the using bi-phasic decline model (Eq.1)

Treatment	N	Delay, t₀ [hr] mean (SD)	HCV RNA clearance rate in serum, c [1/day] mean (SD)	HCV RNA half-life, t_1/2 [hr] mean (SD)	Effectiveness in blocking viral production/release, ε, mean [%](SD)	Second phase slope λ₂ [log₁₀/week] mean (SD)	Loss/death rate of HCV- infected cells, δ [1/day] (SD)
10 or 15 MIU daily IFN ± RBV [11, 105]	31	8.0 (2.4)	8.0 (4.3)	2.7 (1.2)	92.2 (11.2)^*	0.42 (0.36)	0.14 (0.12)
telaprevir monotherapy ^A	36	2.3 (1.6)	13.9 (6.3)	1.4 (0.5)	97.7 (4.2)	4.07 (1.97)	1.34 (0.65)

SD, one standard deviation.

, Model fits (unpublished data) with the same data used in [17•].

With PEG-IFN plus ribavirin therapy, the average effectiveness ε is approximately 67%±30% [101 and even lower in HCV/HIV coinfected individuals [18•, 103].

Estimates are for subjects infected with HCV genotype 1.